Drug Targeting Organ-Specific Strategies

228 8 Strategies for Specific Drug Targeting to Tumour Cells
efforts will be the basis for the introduction of new therapeutics with optimum efficacy and
cost, into clinical practice.
References
[1] Jain RK, Sci. Am. 1994, 271, 58–65.
[2] Jain RK, Science 1996, 271, 1079–1080.
[3] Foulds L, J. Chron. Dis. 1958, 8, 2–37.
[4] Bishop JM, Annu. Rev. Biochem. 1983, 52, 301–354.
[5] Hunter T, Cooper JA, In: Enzyme Control by Protein Phosphorylation. (Eds Boyer PD, Krebs
EG), p. 191. Academic Press, New York, 1986.
[6] Marshall CJ, Cell 1991, 64, 313–326.
[7] De Vita Jr VT, Hellman S, Rosenberg SA (Eds) Cancer, Principles and Practice of Oncology, 5th
edn. J. B. Lippincott Company, Philadelphia, PA, 1997.
[8] Nagy JA, Brown LF, Senger DR, Lanir N, van de Water L, Dvorak AM, Dvorak HF, Biochim.
Biophys. Acta 1988, 948, 305–326.
[9] Folkman J, J. Natl Cancer. Inst. 1990, 82, 4–6.
[10] Griffioen AW, Molema G, Pharmacological Rev. 2000, 52, 237–268.
[11] Bicknell R, Harris AL, Eur. J. Cancer 1991, 27, 781–785.
[12] Polverini PJ, Leibovich SJ, Lab. Invest. 1984, 51, 635–642.
[13] Konerding MA, Steinberg F, Streffer C, Acta Anat. 1989, 136, 21–26.
[14] Jain RK, J. Control. Rel. 1998, 53, 49–67.
[15] Juliano RL, Ling V, Biochim. Biophys. Acta 1976, 455, 152–162.
[16] Cole SPC, Bhardwaj G, Gerlach JH, Machie JE, Grant CE, Almquist KC, Stewart AJ, Kurz EU,
Duncan AMV, Deeley RG, Science 1992, 258, 1650–1654.
[17] Scheffer GL, Wijngaard PLJ, Flens JM, Isquierdo MA, Slovak ML, Pinedo HM, Meijer CJLM,
Clevers HC, Scheper RJ, Nature Med. 1995, 1, 578–582.
[18] Izquierdo MA, Scheffer GL, Flens MJ, Giaccone G, Boxterman HJ, Meijer CJLM, van der Valk
P, Scheper RJ, Am. J. Pathol. 1996, 148, 877–887.
[19] Meijer DK, Smit JW, Hooiveld GJ, Van Montfoort JE, Jansen PL, Muller M, Pharm. Biotechnol.
1999, 12, 89–157.
[20] Wang JC, Biochim. Biophys. Acta 1987, 909, 1–9.
[21] Köhler G, Milstein C, Nature 1997, 256, 495–497.
[22] Farah RA, Clinchy B, Herrera L, Vitetta ES, Crit. Rev. Euk. Gene Expr. 1998, 8, 321–356.
[23] De Leij L, Encycloped. Cancer 1997, 1, 1818–1839.
[24] Demanet C, Brissincle J, De Jonge, Thielemans K, Blood 1996, 81, 4390–4398.
[25] Mellstedt H, Frodin JE, Masucci G, Ragnhammer P, Fagerberg J, Hjelm AL, Shetye J, Wersall P,
Osterborg A, Sem. Oncol. 1991, 18, 462–477.
[26] Hendler FJ, Ozanne BW, J. Clin. Invest. 1984, 74, 647–651.
[27] Berger MS, Gullick WJ, Greenfield C, J. Pathol. 1987, 52, 297–307.
[28] Tateishi M, Ishida T, Mitsudomi T, Sugimachi K, Cancer Res. 1990, 50, 7077–7080.
[29] Schneider PM, Hung MC, Chiocca SM, Cancer Res. 1989, 49, 4968–4971.
[30] Weiner DB, Nordberg J, Robinson R, Cancer Res. 1990, 50, 5184–5191.
[31] Mezzanzanica D, Canevari S, Colnaghi MI, Int. J. Clin. Lab. Res. 1991, 21, 159–164.
[32] Bolhuis RLH, Lamers CHJ, Goey SH, Int. J. Cancer 1992, S7, 78–81.
[33] Miotti S, Canevari S, Menard S, Mezzanzanica D, Porro G, Int. J. Cancer 1987, 39, 297–303.
[34] Bumol TF, Marder P, van de Herdt S, Borowitz MJ, Apelgren LD, Hybridoma 1988, 7, 407–415.
[35] Huang X, Molema G, King S, Watkins L, Edgington TS, Thorpe PE, Science 1997, 275, 547–550.
[36] Ran S, Gao B, Duffy S, Watkins L, Rote N, Thorpe PE, Cancer Res. 1998, 58, 4646–4653.
[37] Molema G, Kroesen BJ, Helfrich W, Meijer DKF, de Leij LFMH, J. Control. Rel. 2000, 64, 229–239.
[38] Clackson T, Hoogenboom M, Griffiths AD, Winter G, Nature 1991, 352, 624–28.
[39] Lobuglio AF, Saleh MN, Am. J. Med. Sci. 1992, 304, 214–224.
[40] Debatin K-M, Krammer PH, Leukaemia 1995, 9, 815–820.
[41] Trauth BC, Klas C, Peters AMJ, Matzhu S, Moller P, Falk W, Debatin K-M, Krammer PH, Science
1989, 245, 301–305.
[42] Gethie M-A, Podar EM, Ilgen A, Gordon BE, Uhr JW, Vitetta ES, Proc. Natl Acad. Sci. USA
1997, 94, 7509–7514.